Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.42 |
| ▸ | NPY1R | P25929 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6597520 | 0.88 | CYP19A1 (0.51) | CYP19A1POLBMAPTMAOBNOS1 | |
| SCHEMBL27532988 | 0.85 | CYP19A1 (0.55) | CYP19A1POLBMAPTMAOBNOS1 | |
| SCHEMBL23320461 | 0.84 | CYP19A1 (0.54) | CYP19A1POLBMAPTMAOBNOS1 | |
| SCHEMBL6257538 | 0.84 | CYP19A1 (0.54) | CYP19A1POLBMAPTMAOBNOS1 | |
| SCHEMBL28007741 | 0.83 | CYP19A1 (0.54) | CYP19A1POLBMAPTMAOBNOS1 | |
| SCHEMBL27602612 | 0.82 | CYP19A1 (0.52) | CYP19A1POLBMAPTMAOBNOS1 | |
| SCHEMBL28788157 | 0.82 | CYP19A1 (0.46) | CYP19A1POLBMAPTMAOBNOS1 | |
| SCHEMBL29697809 | 0.82 | CYP19A1 (0.46) | CYP19A1POLBMAPTMAOBNOS1 | |
| SCHEMBL7807147 | 0.81 | KDM4E (0.55) | CYP19A1POLBMAPTMAOBNOS1 | |
| SCHEMBL10583924 | 0.80 | CYP19A1 (0.50) | CYP19A1POLBMAPTMAOBNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111171040-A | Dihydrofuropyran/pyridoindole derivatives and synthesis method thereof | 常州大学 | 2020-05-19 | — | — | CN | claimed |
| EP-4746922-A2 | INTERLEUKIN-13 RECEPTOR SUBUNIT ALPHA-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747282-A1 | ACTIVATABLE TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR (ROR) ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747283-A1 | TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR 1 (ROR1) ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4583922-A2 | TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Exelixis, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| CN-120129535-A | Tissue factor antibody-drug conjugates and uses thereof | 埃克塞里艾克西斯公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2025019780-A9 | ACTIVATABLE TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR (ROR) ANTIBODY-DRUG CONJUGATES AND USES THEREOF | EXELIXIS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119775261-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2025019787-A1 | TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR 1 (ROR1) ANTIBODY-DRUG CONJUGATES AND USES THEREOF | EXELIXIS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025019776-A2 | INTERLEUKIN-13 RECEPTOR SUBUNIT ALPHA-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | EXELIXIS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | BYONDIS B.V. (NL) | 2011-08-25 | — | — | US | disclosed |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | BYONDIS B.V. (NL) | 2011-08-25 | — | — | US | disclosed |
| WO-2010062171-A2 | NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2010-06-03 | — | — | WO | disclosed |
| US-7094798-B1 | Inhibitors of checkpoint kinases (Wee1 and Chk1) | PFIZER INC (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1501831-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091255-A1 | INHIBITORS OF CHECKPOINT KINASES (WEE1 AND CHK1) | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-0918752-A4 | DNA-BINDING INDOLE DERIVATIVES, THEIR PRODRUGS AND IMMUNOCONJUGATES AS ANTICANCER AGENTS | PANORAMA RES INC (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-0918752-A2 | DNA-BINDING INDOLE DERIVATIVES, THEIR PRODRUGS AND IMMUNOCONJUGATES AS ANTICANCER AGENTS | PANORAMA RESEARCH, INC. (US) | 1999-06-02 | — | — | EP | disclosed |
| US-5843937-A | DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents | PANORAMA RESEARCH, INC. (US) | 1998-12-01 | — | — | US | disclosed |
| WO-1997044000-A2 | DNA-BINDING INDOLE DERIVATIVES, THEIR PRODRUGS AND IMMUNOCONJUGATES AS ANTICANCER AGENTS | PANORAMA RESEARCH, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | PCNA, CDC5L, TOP1 | CYP19A1 3882/4885POLB 221/4885MAPT 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.